Dermatology and Skin Cancer Specialists, LLC

Rockville, Maryland 20850

2 studies enrolling now · 9 studies all time

What they study most

Active Nonsegmental Vitiligo, Alopecia Areata, Atopic Dermatitis, Dermatitis, Atopic, Obesity, Overweight or Obesity, Plaque Psoriasis, Psoriasis, Stable Nonsegmental Vitiligo

Studies at this site

• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis — Recruiting now
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Recruiting now
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 — Running, not enrolling
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight — Completed
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Running, not enrolling
• A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis — Completed
• A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis — Completed